AB Corporate Bond ETF (NASDAQ:EYEG) Trading 0.3% Higher – What’s Next?

Shares of AB Corporate Bond ETF (NASDAQ:EYEG) shot up 0.3% on Wednesday . The stock traded as high as $35.42 and last traded at $35.4010. 116 shares changed hands during trading, a decline of 41% from the average session volume of 195 shares. The stock had previously closed at $35.30.

AB Corporate Bond ETF Stock Up 0.3%

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07. The company has a market capitalization of $28.32 million, a price-to-earnings ratio of -21.07 and a beta of 0.23. The firm has a 50-day moving average price of $35.59 and a two-hundred day moving average price of $35.88.

AB Corporate Bond ETF Increases Dividend

The company also recently disclosed a monthly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Wednesday, April 1st were given a dividend of $0.1433 per share. This is an increase from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) annualized dividend and a dividend yield of 4.9%. The ex-dividend date of this dividend was Wednesday, April 1st. AB Corporate Bond ETF’s payout ratio is currently -104.17%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC boosted its position in shares of AB Corporate Bond ETF by 166.7% during the fourth quarter. Jane Street Group LLC now owns 15,741 shares of the specialty pharmaceutical company’s stock worth $563,000 after buying an additional 9,839 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of AB Corporate Bond ETF during the fourth quarter worth about $34,000. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of AB Corporate Bond ETF by 32.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after buying an additional 38,685 shares during the period. 64.16% of the stock is owned by institutional investors and hedge funds.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.